Cancer Immunotherapies Have FDA, Industry Looking For New Endpoints

Modifying existing tumor response criteria or developing novel intermediate endpoints could address shortfalls in immuno-oncology efficacy assessments with traditional endpoints such as overall response rate and progression-free survival.